Labiotech.eu

More News! 19 Jul 2019

UK VC Medicxi Closes Third Fund with €400M to Boost European Biotech

The UK-based venture capital investment firm Medicxi has closed its third fund, totaling €400M, to nurture early- and late-stage healthcare biotech companies in Europe. The firm will begin investing in the first beneficiary companies of this fund in the next few months. The big round was raised in just six weeks, and dwarfs Medicxi’s previous […]

July 19, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 18 Jul 2019

Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs

The Danish biotech Genmab has made a big splash on the Nasdaq, raising a €450M ($506M) IPO to fuel its antibody drug programs in cancer, autoimmune diseases, and more. This IPO is one of the biggest in biotech history, behind the whopping €530M Nasdaq entry from US mRNA biotech Moderna last year. It’s also to […]

July 18, 2019 - 2 minutesmins - By Jonathan Smith

pneumonia polyphor antibiotic murepravadin

More News! 18 Jul 2019

Swiss Pneumonia Antibiotic Abandoned in Phase III

The Swiss biotech Polyphor has discontinued two phase III trials of its antibiotic for treating pneumonia after halting both trials due to safety concerns in May. The two phase III trials were testing Polyphor’s intravenous antibiotic murepavadin in hospitalized patients with pneumonia. In May, Polyphor halted the two trials due to an unexpectedly high incidence […]

July 18, 2019 - 2 minutesmins - By Jonathan Smith

anthrax treatment belgium VIB nanobodies

More News! 17 Jul 2019

Scientists in Belgium Cure Anthrax in Mice by Smashing Bacteria’s Armor

Belgian researchers have developed a potential treatment for anthrax that breaks down the bacteria’s thick protein armor. Anthrax is a deadly type of bacteria famous for its use in terrorist attacks in 2001. Although anthrax infections can be treated with antibiotics, they can prove hard to treat when the bacteria are inhaled or ingested. Scientists […]

July 17, 2019 - 2 minutesmins - By Jonathan Smith

boehringer ingelheim cancer vaccine amal therapeutics

News and Trends 16 Jul 2019

Boehringer Ingelheim Acquires Cancer Vaccine Biotech in €325M Deal

The German giant Boehringer Ingelheim has acquired the Swiss company AMAL Therapeutics and its cancer vaccine technology in a deal worth up to €325M. The deal includes €225M in upfront and developmental milestone payments, as well as up to €100M in undisclosed commercial milestone payments. AMAL’s vaccine development pipeline includes five preclinical programs. The lead […]

July 16, 2019 - 2 minutesmins - By Jonathan Smith

Opinion 16 Jul 2019

The Business of Biotech: What to Do When the S*#t Hits the Fan

From CEO-itis to FDA-itis, the path of a biotech company is never dull. Whether the oft-repeated saying, “may you live in interesting times,” is a blessing or a curse depends entirely on your perspective. As a life science venture capital investor with close to 25 years of experience, I have encountered many unexpected and interesting […]

July 16, 2019 - 5 minutesmins - By Antoine Papiernik

graphene bacteria rochester delft university

News and Trends 15 Jul 2019

Dutch-US Scientists Use Bacteria to Produce Graphene for Electronics

An international group of researchers has made graphene more affordably and with a lower environmental impact than current chemical methods by using bacteria. Graphene is a very strong and conductive material that could revolutionize electronics and engineering. However, producing graphene in large quantities requires lots of energy and involves toxic chemicals, such as hydrazine, which […]

July 15, 2019 - 2 minutesmins - By Jonathan Smith

gilead galapagos arthritis pulmonary fibrosis

News and Trends 15 Jul 2019

Gilead Pays Billions for Access to Galapagos’ Pipeline

Gilead has launched a 10-year collaboration with the Belgo-Dutch biotech Galapagos, paying at least €4.5B ($5.1B) for commercial rights to Galapagos’s whole pipeline, including a phase III drug for pulmonary fibrosis. As part of the deal, Gilead will pay Galapagos €3.5B ($3.95B) upfront, with a further €1B ($1.1B) in equity investment. In return, Gilead gets […]

July 15, 2019 - 2 minutesmins - By Jonathan Smith

omics aromics barcelona panorama mesothelioma

Startup Scout 12 Jul 2019

This Biotech Uses ‘Omics’ to Develop Treatments for Drug-Resistant Cancer

Next time you travel to Barcelona, Spain, check out Aromics, a biotech that is using genomics and proteomics to develop treatments for cancers such as malignant mesothelioma, which can be caused by asbestos. Mission: To use omics technology to treat drug-resistant cancers, as well as to identify cancer biomarkers that could improve monitoring in clinical […]

July 12, 2019 - 3 minutesmins - By Jonathan Smith

bayer bacteriophage ecophage agriculture

More News! 11 Jul 2019

Bayer Launches Israeli Company to Develop Viruses Against Crop Disease

Bayer is backing the launch of the Israeli biotech Ecophage, which will develop environmentally friendly crop disease treatments based on bacteria-hunting viruses called bacteriophages. Bacteria can cause a range of diseases in crops, including blight and root rot. These infections are often hard to control because they happen faster than fungal infections. The treatments used […]

July 11, 2019 - 2 minutesmins - By Jonathan Smith

microphyt microalgae obesity cognitive decline

More News! 11 Jul 2019

French Company Raises €29M to Sell Supplements and Cosmetics from Microalgae

The French biotech Microphyt has raised €28.5M ($32M) to commercialize nutritional and cosmetic products harvested from microalgae. Over the next 18 months, Microphyt will use the money to ramp up its workforce and industrial capacity in preparation for pushing its microalgal food ingredients and cosmetics to market. The company is developing technology to overcome a […]

July 11, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 10 Jul 2019

French Startup’s Universal Flu Vaccine Development Boosted by €8M Series A

The French biotech Osivax has advanced in the race to develop a universal flu vaccine, raising €8M to achieve clinical proof-of-concept. Osivax will use most of the funding to progress its lead candidate vaccine towards market approval. Targeting all strains of influenza A viruses, the vaccine is currently in a phase I trial, with results […]

July 10, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

UK VC Medicxi Closes Third Fund with €400M to Boost European Biotech

Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs

Swiss Pneumonia Antibiotic Abandoned in Phase III

Scientists in Belgium Cure Anthrax in Mice by Smashing Bacteria’s Armor

Boehringer Ingelheim Acquires Cancer Vaccine Biotech in €325M Deal

The Business of Biotech: What to Do When the S*#t Hits the Fan

Dutch-US Scientists Use Bacteria to Produce Graphene for Electronics

Gilead Pays Billions for Access to Galapagos’ Pipeline

This Biotech Uses ‘Omics’ to Develop Treatments for Drug-Resistant Cancer

Bayer Launches Israeli Company to Develop Viruses Against Crop Disease

French Company Raises €29M to Sell Supplements and Cosmetics from Microalgae

French Startup’s Universal Flu Vaccine Development Boosted by €8M Series A

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!